References cited
Article section 15 of 16.  Previous  Next

By Wendy Sherman and Jeffrey Raizer

Adams EF, Todo T, Schrell UM, Thierauf P, White MC, Fahlbusch R. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer 1991;49:398-402.

Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009;64(1):56-60.

Aguiar PH, Tsanaclis AM, Tella OL Jr, Plese JP. Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics. Neurosurg Rev 2003;26:221-8.

Annegers JF, Laws ER, Kurland LT, Grabow JD. Head trauma and subsequent brain tumors. Neurosurgery 1979;4:203-6.

Bagni A, Botticelli A, Martinelli A, Azzoni P, Trentini GP. AgNOR counts in recurrent and non-recurrent meningiomas. Histopathology 1991;19:465-7.

Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, Lal A. Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia 2008;10(6):604-12.

Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987;20:525-8.

Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int J Cancer 2010;127(7):1692-8.

Bickerstaff ER, Small JM, Guest LA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 1958;21:89-91.

Blaauw G, Koudstaal J, Blankenstein MA, Debets-Te Baerts M, Gijzen AH. Projestin receptors in meningiomas. Comparison of cytosolic assays with immunocytochemical identification in cryostat and paraffin sections. Acta Neurochir (Wien) 1995;134:83-7.

Black P, Carroll R, Zhang J. The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir (Suppl) 1996;65:50-3.

Boldrini L, Pistolesi S, Gisfredi S, et al. Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Archiv 2006;449(5):546-53.

Bollag RJ, Vender JR, Sharma S. Anaplastic meningioma: Progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Neuropathology 2010;30(3):279-87.

Bostrom J, Muhlbauer A, Reifenberger G. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol (Berl) 1997;94(5):479-85.

Bouillot P, Pellissier JF, Devictor B, et al. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 1994;81:765-73.

Bouvier C, Liprandi A, Colin C, et al. Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol 2005;124(2):252-8.

Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS 2009;117(9):651-9.

Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013;45:285-9.

Braunstein JB, Vick NA. Meningiomas: the decision not to operate. Neurology 1997;48(5):1459-62.

Buhl R, Nabavi A, Wolff S, et al. MR spectroscopy in patients with intracranial meningiomas. Neurol Res 2007;29(1):43-6.

Cabuy E, de Ridder L. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch 2001;439(2):176-84.

Caltabiano R, Barbagallo GM, Castaing M, et al. Prognostic value of EGFR expression in de novo and progressed atypical and Anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study. J Neurosurg Sci 2013;57(2):139-51.

Campbell BA, Jhamb A, Maguire JA, Toyota B, Ma R. Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol 2009;32(1):73-5.

Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996;84:733-6.

Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 2012;107:315-21.

Chamberlain MC, Glantz MJ. Cerebrospinal fluid-disseminated meningioma. Cancer 2005;103(7):1427-30.

Chamberlain MC, Glantz MJ. Alpha-interferon for recurrent WHO grade I intracranial meningiomas. Cancer 2008;113:2146-51.

Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007;69(10):969-73.

Chang Z, Guo CL, Ahronowitz I, et al. A role for the p53 pathway in the pathology of meningiomas with NF2 loss. J Neurooncol 2009;91(3):265-70.

Chen HJ, Liang CL, Lu K, Lin JW, Cho CL. Implications of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 2000;89(10):2092-8.

Christiaans I, Kenter SB, Brink HC, et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 2011;48(2):93-7.

Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077-80.

Coke CC, Corn BW, Werner-Wasik M, Xie Y, Curran WJ. Atypical and malignant meningiomas: an outcome report of seventeen cases. J Neurooncol 1998;39(1):65-70.

Cuevas IC, Slocum AL, Jun P, et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 2005;65(12):5070-5.

Cushing H. The meningiomas (dural endotheliomas): their source, and favoured seats of origin. Brain 1922;45:282-316.

Cushing H, Eisenhardt L. Meningiomas: their classification, regional behaviour, life history, and surgical end results, part I and part II. New York: Hafner Publ, 1962.

DeMonte F, Al-Mefty O. Meningiomas. In: Kaye AH, Laws ER, editors. Brain tumors. An encyclopedic approach. New York: Churchill Livingstone, 1995:675-704.

Doron Y, Gruszkiewicz J. Metastasis of invasive carcinoma of the breast to an extradural meningioma of the cranial vault. Cancer 1987;60:1081-4.

Dowd CF, Halbach VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 2003;15(1):E10.

Duma CM, Lunsford LD, Kondziolka D, Harsh GR 4th, Flickinger JC. Stereotactic radiosurgery of cavernous sinus meningiomas as an addition or alternative to microsurgery. Neurosurgery 1993;32(5):699-704.

Elster AD, Challa VR, Gilbert TH, Richardson DN, Contento JC. Meningiomas: MR and histopathologic features. Radiology 1989;170:857-62.

Fewings PE, Battersby RD, Timperley WR. Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg 2000;92(3):401-5.

Filippi CG, Edgar MA, Ulug AM, et al. Appearance of meningiomas on diffusion-weighted images: correlating diffusion constants with histopathologic findings. AJNR Am J Neuroradiol 2001;22(1):65-72.

Friedman WA, Murad GJ, Bradshaw P, et al. Linear accelerator surgery for meningiomas. J Neurosurg 2005;103(2):206-9.

Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg 2009;111(3):464-71.

Glaholm J, Bloom HJG, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990;18:755-61.

Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998;51(6):1718-20.

Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997;40(6):1269-77.

Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967-1990. J Neurosurg 1994;80:195-201.

Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. J Neurooncol 1993;15:75-7.

Gruber T, Dare AO, Balos LL, Lele S, Fenstermaker RA. Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. J Neurosurg 2004;100(2):328-31.

Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of Mifepristone (RU-486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24(8):727-33.

Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9(10):1495-500.

Han J, Girvigian MR, Chen JC, et al. A comparative study of stereotactic radiosurgery, hypofractionated, and fractionated stereotactic radiotherapy in the treatment of skull base meningioma. Am J Clin Oncol 2012. [Epub ahead of print]

Hao S, Smith TW, Chu PG, et al. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med 2011;135(8):1032-6.

Harada T, Irving RM, Xuereb JH, et al. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996;84:847-51.

Harrison MJ, Wolfe DE, Lau TS, Mitnick RJ, Sachdev VP. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg 1991;75:564-74.

Herscovici Z, Rappaport Z, Sulkes J, Danaila L, Rubin G. Natural history of conservatively treated meningiomas. Neurology 2004;63(6):1133-4.

Hirashima Y, Hayashi N, Fukuda O, Ito H, Endo S, Takaku A. Platelet-activating factor and edema surrounding meningiomas. J Neurosurg 1998;88(2):304-7.

Horak P, Wohrer A, Hassler M, et al. Imatinib mesylate treatment for recurrent meningioma in preselected patients: a retrospective analysis. J Neurooncol 2012;109:323-30.

Horsfall DJ, Goldsmith KG, Ricciardelli C, Skinner JM, Tilley WD, Marshall VR. Steroid hormone and epidermal growth factor receptors in meningiomas. Aust N Z J Surg 1989;59:881-8.

Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997;86:113-20.

Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.

Johnson MD, O’Connell M, Pilcher W. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neurooncol 2011;101(3):441-8.

Johnson MD, O'Connell M, Vito F, Bakos RS. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphidylinositol 3-Kinase-Act-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol 2009a;92(2):129-36.

Johnson MD, O'Connell MJ, Vito F, Pilcher W. Bone morphogenic protein 4 and its receptors are expressed in the leptomeninges and meningiomas and signal via the SMAD pathway. J Neuropathol Exp Neurol 2009b;68(11):1177-83.

Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 2001;94(2):293-300.

Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon-alpha-2b. Neurosurgery 1997;40:271-5.

Kalala JP, Maes L, Vandenbroecke C, deRidder L. The hTERT protein as a marker for malignancy in meningiomas. Oncology Reports 2005;13(2):273-7.

Kane AJ, Sughrue ME, Rutkowski MJ, et al. Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 2011;117(6):1272-8.

Kano H, Takahashi JA, Katsuki T, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol 2007;84(1):41-7.

Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;29(2):140-5.

Khalid H. Immunohistochemical study of estrogen receptor-related antigen, progesterone, and estrogen receptors in human intracranial meningiomas. Cancer 1994;74:679-85.

Khalid H, Yasunaga A, Kishikawa M, Shibata S. Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors. Cancer 1995;75:2571-8.

Kim EY, Weon YC, Kim ST, et al. Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients. AJNR 2007;28(8):1462-5.

Kim JH, Lee SH, Rhee CH, Park SY, Lee JH. Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neurooncol 1998;40(2):101-6.

Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. 2nd ed. World Health Organization. Berlin: Springer-Verlag, 1993:30.

Knuckey NW, Stoll J, Epstein MH. Intracranial and spinal meningiomas in patients with breast carcinoma: case reports. Neurosurgery 1989;25:112-7.

Kokubo M, Shibamoto Y, Takahashi JA, et al. Efficacy of conventional radiotherapy for recurrent meningioma. J Neurooncol 2000;48(1):51-5.

Kollova A, Liscak R, Novotny J Jr, Vladyka V, Simonova G, Janouskova L. Gamma Knife surgery for benign meningioma. J Neurosurg 2007;107(2):325-36.

Komotar RJ, Iorqulescu JB, Raper DM, et al. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neuorsurg 2012;117:679-86.

Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. Am J Neuroradiol 2001;22(6):1081-8.

Konstantinidou AE, Pavlopoulos PM, Patsouris E, Kaklamanis L, Davaris P. Expression of apoptotic and proliferation markers in meningiomas. J Pathol 1998;186(3):325-30.

Korshunov A, Cherekaev V, Bekyashev A, Sycheva R. Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol 2007;81(2):131-7.

Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol 2011;12(13):1229-39.

Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G. Long term experience of gamma knife radiosurgery for benign skull base meningiomas (Review). J Neurol Neurosurg Psychiatry 2005;76(10):1425-30.

Kumar PP, Patil AA, Leibrock LG, et al. Brachytherapy: a viable alternative in the management of basal meningiomas. Neurosurgery 1991;29:676-80.

Kuratsu J, Kochi M, Ushio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 2000;92(5):766-70.

Kuratsu JI, Seto H, Kochi M, Ushio Y. Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma. Acta Neurochir (Wien) 1994;131:289-93.

Larson JJ, Tew JM, Simon M, Menon AG. Evidence for clonal spread in the development of multiple meningiomas. J Neurosurg 1995;83:705-9.

Lee JW, Kang KW, Park SH, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 2009;36(10):1574-82.

Lee JY, Kondziolka D, Flickinger JC, Lunsford LD. Radiosurgery for intracranial meningiomas. Prog Neurologic Surg 2007;20:142-9.

Lee JY, Niranjan A, McInerney J, et al. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg 2002;97(1):65-72.

Leuraud P, Dezamis E, Aguirre-Cruz L, et al. Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 2004;100(2):303-9.

Lichtenbaum R, de Souza AA, Jafar JJ. Intratumoral hydrogen peroxide injection during meningioma resection. Neurosurgery 2006;59(4 Suppl 2):ONS470-3.

MacCarty CS, Taylor WF. Intracranial meningiomas: experiences at the Mayo Clinic. Neurol Med Chir (Tokyo) 1979;19:569-74.

Mack EE, Wilson CB. Meningiomas induced by high-dose cranial irradiation. J Neurosurg 1993;79:28-31.

Maes L, Lippens E, Kalala JP, de Ridder L. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Proliferation 2005;38(1):3-12.

Maguire PD, Clough R, Friedman AH, Halperin EC. Fractionated external-beam radiation therapy for meningiomas of the cavernous sinus. Int J Radiat Oncol Biol Phys 1999;44(1):75-9.

Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-23.

Malmer B, Tavelin B, Henriksson R, Gronberg H. Primary brain tumors as second primary: a novel association between meningioma and colorectal cancer. Int J Cancer 2000;85(1):78-81.

Mathiesen T, Kihlstrom L, Karlsson B, Lindquist C. Potential complications following radiotherapy for meningiomas. Surg Neurol 2003;60:193-8.

McCarthy BJ, Davis FG, Freels S, et al. Factors associated with survival in patients with meningioma. J Neurosurg 1998;88(5):831-9.

McGovern SL, Aldape KD, Munsell MF, Mahajan A, Demonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 2010;112(5):925-33.

Menon AG, Rutter JL, von Sattel JP, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative ‘tumor progression’ locus. Oncogene 1997;14(5):611-6.

Miller DC, Ojemann RG, Proppe KH, McGinnis BD, Grillo HC. Benign metastasizing meningioma. Case report. J Neurosurg 1985;62:763-6.

Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. Lancet 1974;1:277-9.

Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of incidental meningiomas. Neurosurg 2003;53:62-70.

Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 2009;26(2):69-72.

Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012;109:187-93.

Newman SA. Meningiomas: a quest for the optimum therapy. J Neurosurg 1994;80:191-4.

Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2001;49(2):165-70.

Nicolato A, Foroni R, Alessandrini F, et al. The role of gamma knife radiosurgery in the management of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 2002;53(4):992-1000.

Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010;96(2):211-7.

Nordqvist AC, Peyrard M, Pettersson H, et al. A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 1997;57(13):2611-4.

Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer 1994;74:3176-89.

Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 1995;83:222-4.

Opstad KS, Provencher SW, Bell BA, Griffiths JR, Howe FA. Detection of elevated glutathione in meningiomas by quantitative in vivo 1H MRS. Magn Reson Med 2003;49:632-7.

Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997;86(5):793-800.

Panagopoulous AT, Lancellotti CL, Veig JC, de Atuiar PH, Colquhoun A. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol 2008;89(1):73-87.

Pannullo SC, Fraser JF, Moliterno J, Cobb W, Stieg PE. Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease. J Neurooncol 2011;103(1):1-17.

Park KJ, Kang SH, Chae YS, et al. Influence of Interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg 2010;112(1):73-80.

Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59(10):872-9.

Perry A, Scheithauer BW, Stafford SL, et al. “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85(9):2046-56.

Peyrard M, Seroussi E, Sandberg-Nordqvist AC, et al. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc Natl Acad Sci U S A 1999;96(2):598-603.

Piaskowski S, Rieske P, Szybka M, et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 2005;162(1):63-7.

Pollock BE, Stafford SL. Results of stereotactic radiosurgery for patients with imaging defined cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 2005;62(5):1427-31.

Probst EN, Grzyska U, Westphal M, Zeumer H. Preoperative embolization of intracranial meningiomas with a fibrin glue preparation. AJNR Am J Neuroradiol 1999;20(9):1695-702.

Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997;40(5):1016-26.

Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 2010;21(12):2445-6.

Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995;37:67-73.

Rawat B, Franchetto AA, Elavathil J. Extracranial metastases of meningioma. Neuroradiology 1995;37:38-41.

Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999;5(2):237-41.

Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989;134:337-44.

Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003;13:191-202.

Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg 1989;71:665-72.

Sakuma T, Nakagawa T, Ido K, Takeuchi H, Sato K, Kubota T. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J Neurooncol 2008;88(2):143-55.

Saydam O, Shen Y, Wurdinger T, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009;29(21):5923-40.

Schmitz U, Mueller W, Weber M, Sevenet N, Delattre O, von Deimling A. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001;84(2):199-201.

Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975;25:705-12.

Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997;86(5):840-4.

Sheehy JP, Crockard HA. Multiple meningiomas: a long-term review. J Neurosurg 1983;59:1-5.

Shibuya M, Hoshino T, Ito S, et al. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling. Neurosurgery 1992;30:494-8.

Shoshan Y, Chernova O, Juen SS, et al. Radiation-induced meningioma: a distinct molecular genetic pattern? J Neuropathol Exp Neurol 2000;59(7):614-20.

Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ. Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 2008;70(5):471-7.

Simon M, Park TW, Koster G, et al. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 2001;55(3):149-58.

Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 2009;92(1):1-6.

Solan MJ, Kramer S. The role of radiation therapy in the management of intracranial meningiomas. Int J Radiat Oncol Biol Phys 1985;11:675-7.

Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998;73(10):936-42.

Sulman EP, Dumanski JP, White PS, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 1998;58(15):3226-30.

Swerdlow AJ, Feychting M, Green AC, et al. Mobile phones, brain tumors, and the interphone study: where are we now? Environ Health Perspect 2011;119(11):1534-8.

Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg Neurol 1997;48(5):501-6.

Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010;28(36):5287-93.

Taylor BW, Marcus RB, Friedman WA, Ballinger WE, Million RR. The meningioma controversy: postoperative radiation therapy. J Radiat Oncol Biol Phys 1988;15:299-304.

Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 1996;84:852-9.

Tong-tong W, Li Juan B, Zhi L, Yang L, Bo-Ning L, Quan H. Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract 2010;206(5):349-54.

Tse JY, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP. Loss of heterozygosity of chromosome 14q in low-and high-grade meningiomas. Hum Pathol 1997;28(7):779-85.

Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 1999;59(23):5995-8.

Vadivelu S, Sharer L, Schulder M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg 2010;112(5):920-4.

van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC. Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 2007;84(3)271-8.

Vernimmen FJ, Harris JK, Wilson JA, et al. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 2001;49(1):99-105.

Vranic A, Popovic M, Cor A, Prestor B, Pizem J. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 2010;67(4):1124-32.

Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94(26):14719-24.

Wenkel E, Thornton AF, Finkelstein D, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys 2000;48(5):1363-70.

Westphal M, Herrmann HD. Epidermal growth factor-receptors on cultured meningioma cells. Acta Neurochir (Wien) 1986;83:62-6.

Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir 2000;142(5):507-11.

Yoo H, Baia GS, Smith JS, et al. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res 2007;13(1):68-75.

Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM. Tissue transgluaminase 2 expression in meningiomas. J Neurooncol 2008;90(2):125-32.

Zimny A, Sasiadek M. Contribution of perfusion-weighted magnetic resonance imaging in the differentiation of meningiomas and other extra-axial tumors: case reports and literature review. J Neurooncol 2011;103(3):777-83.

**References especially recommended by the author or editor for general reading.

In This Article

Historical note and nomenclature
Clinical manifestations
Clinical vignette
Pathogenesis and pathophysiology
Differential diagnosis
Diagnostic workup
Prognosis and complications
References cited